The Delhi High Court today told Swiss pharma major Roche that it "cannot hang on to" breast cancer drug Trastuzumab, innovated by it, for the rest of its life after having enjoyed the fruits of its patent.
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Biocon will be in focus in today‘s trading session because they have launched one of the key breast cancer drugs in partnership with Mylan in the Indian market. Here‘s Ekta Batra on CNBC-TV18 with details on that.
Indian generic drug maker BDR Pharma's plans could draw new battles lines over intellectual property rights. After seeking a compulsory license for leukemia drug Sprycel, BDR Pharma is setting its sight on more patent-protected anti-cancer drugs, reports CNBC-TV18's Archana Shukla.